Drug Class Review on Second Generation Antidepressants: Final Report [Internet]

Gerald Gartlehner; Richard A Hansen; Leila Kahwati; Kathleen N Lohr; Bradley Gaynes; Tim Carey

Drug Class Review on Second Generation Antidepressants: Final Report [Internet]

Review

Portland (OR): Oregon Health & Science University; 2006 Mar.

Drug Class Reviews.

Authors

Gerald Gartlehner¹, Richard A Hansen¹, Leila Kahwati¹, Kathleen N Lohr¹, Bradley Gaynes¹, Tim Carey¹

Affiliation

¹ RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, 725 Airport Road, CB# 7590, Chapel Hill, NC 27599-7590, Tim Carey, MD, MPH, Director.

PMID: 20480925
Bookshelf ID: NBK10326

Excerpt

Axis I psychiatric disorders such as depressive disorder, anxiety disorder, adjustment disorder, and premenstrual disorders are serious disabling illnesses. Newer treatments for these disorders include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other second-generation drugs. The purpose of this review is to help policymakers and clinicians make informed choices about the use of SSRIs and newer antidepressants.

Sections

Publication types

Review

Grants and funding

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.